Udaya Kompella
Concepts (723)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Delivery Systems | 39 | 2021 | 327 | 7.990 |
Why?
| Nanoparticles | 33 | 2022 | 369 | 5.310 |
Why?
| Retina | 27 | 2020 | 274 | 4.630 |
Why?
| Eye Diseases | 11 | 2021 | 80 | 3.240 |
Why?
| Sulfonamides | 17 | 2017 | 495 | 3.210 |
Why?
| Choroid | 14 | 2020 | 61 | 2.830 |
Why?
| Pyrazoles | 14 | 2014 | 404 | 2.490 |
Why?
| Eye | 12 | 2017 | 105 | 2.470 |
Why?
| Drug Carriers | 14 | 2019 | 116 | 2.240 |
Why?
| Vascular Endothelial Growth Factor A | 24 | 2017 | 503 | 2.220 |
Why?
| Triptorelin Pamoate | 14 | 2009 | 19 | 2.220 |
Why?
| Ophthalmic Solutions | 12 | 2025 | 73 | 2.180 |
Why?
| Polyglycolic Acid | 16 | 2015 | 42 | 2.080 |
Why?
| Budesonide | 9 | 2020 | 88 | 2.030 |
Why?
| Lactic Acid | 17 | 2015 | 294 | 2.010 |
Why?
| Delayed-Action Preparations | 17 | 2020 | 170 | 1.960 |
Why?
| Pharmaceutical Preparations | 8 | 2022 | 168 | 1.800 |
Why?
| Pigment Epithelium of Eye | 11 | 2012 | 34 | 1.760 |
Why?
| Gene Transfer Techniques | 8 | 2014 | 162 | 1.750 |
Why?
| Sclera | 9 | 2012 | 36 | 1.700 |
Why?
| Animals | 117 | 2025 | 34647 | 1.650 |
Why?
| Diabetic Retinopathy | 8 | 2018 | 172 | 1.630 |
Why?
| Diabetes Mellitus, Experimental | 9 | 2018 | 175 | 1.630 |
Why?
| Particle Size | 16 | 2020 | 352 | 1.590 |
Why?
| Conjunctiva | 14 | 2009 | 51 | 1.430 |
Why?
| Rabbits | 28 | 2022 | 775 | 1.420 |
Why?
| Enzyme Inhibitors | 10 | 2011 | 813 | 1.390 |
Why?
| Tandem Mass Spectrometry | 8 | 2022 | 456 | 1.380 |
Why?
| Retinal Pigment Epithelium | 7 | 2013 | 69 | 1.370 |
Why?
| Nanostructures | 4 | 2019 | 99 | 1.370 |
Why?
| Blood-Retinal Barrier | 6 | 2013 | 12 | 1.350 |
Why?
| Rats | 34 | 2020 | 5246 | 1.290 |
Why?
| Sulfones | 6 | 2012 | 108 | 1.290 |
Why?
| Vitreous Body | 13 | 2020 | 108 | 1.290 |
Why?
| Dexamethasone | 4 | 2020 | 345 | 1.280 |
Why?
| Cyclooxygenase Inhibitors | 6 | 2008 | 80 | 1.270 |
Why?
| Rats, Sprague-Dawley | 26 | 2020 | 2272 | 1.220 |
Why?
| Drug Compounding | 6 | 2020 | 96 | 1.210 |
Why?
| Melanins | 4 | 2012 | 17 | 1.210 |
Why?
| Capillary Permeability | 6 | 2011 | 131 | 1.200 |
Why?
| Anti-Inflammatory Agents | 7 | 2020 | 470 | 1.130 |
Why?
| Glucocorticoids | 7 | 2021 | 573 | 1.120 |
Why?
| Polymers | 8 | 2013 | 475 | 1.100 |
Why?
| Cattle | 18 | 2021 | 965 | 1.090 |
Why?
| Receptors, LHRH | 5 | 2009 | 14 | 1.070 |
Why?
| Glycine | 6 | 2009 | 163 | 1.050 |
Why?
| Aldehyde Reductase | 5 | 2007 | 28 | 1.050 |
Why?
| Cornea | 10 | 2015 | 127 | 1.010 |
Why?
| RNA, Small Interfering | 5 | 2017 | 573 | 0.990 |
Why?
| Nanotechnology | 5 | 2019 | 121 | 0.990 |
Why?
| Nasal Mucosa | 6 | 2009 | 107 | 0.970 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2012 | 335 | 0.960 |
Why?
| Eye Infections, Parasitic | 1 | 2025 | 2 | 0.960 |
Why?
| Blepharitis | 1 | 2025 | 5 | 0.960 |
Why?
| Mite Infestations | 1 | 2025 | 6 | 0.950 |
Why?
| Celecoxib | 14 | 2014 | 39 | 0.950 |
Why?
| Intercellular Signaling Peptides and Proteins | 5 | 2013 | 372 | 0.940 |
Why?
| Naphthalenes | 1 | 2025 | 56 | 0.930 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 215 | 0.920 |
Why?
| alpha-Crystallin B Chain | 2 | 2022 | 24 | 0.890 |
Why?
| Epithelial Cells | 8 | 2016 | 1043 | 0.890 |
Why?
| Retinal Degeneration | 3 | 2020 | 37 | 0.870 |
Why?
| Dendrimers | 4 | 2012 | 13 | 0.860 |
Why?
| Chromatography, Liquid | 7 | 2022 | 381 | 0.850 |
Why?
| Endothelial Growth Factors | 5 | 2003 | 51 | 0.850 |
Why?
| Lymphokines | 5 | 2003 | 115 | 0.840 |
Why?
| Gonadotropin-Releasing Hormone | 5 | 2006 | 207 | 0.820 |
Why?
| Tomography, Optical Coherence | 2 | 2021 | 186 | 0.810 |
Why?
| Cyprinidae | 1 | 2022 | 20 | 0.810 |
Why?
| Intraocular Pressure | 4 | 2020 | 297 | 0.810 |
Why?
| Cyclooxygenase 2 Inhibitors | 6 | 2014 | 21 | 0.810 |
Why?
| Choroidal Neovascularization | 6 | 2017 | 52 | 0.800 |
Why?
| Sotalol | 1 | 2022 | 6 | 0.800 |
Why?
| Administration, Topical | 11 | 2020 | 144 | 0.790 |
Why?
| Insulins | 1 | 2022 | 37 | 0.760 |
Why?
| Awards and Prizes | 1 | 2022 | 60 | 0.760 |
Why?
| Tissue Distribution | 10 | 2019 | 296 | 0.760 |
Why?
| Lymphocyte Function-Associated Antigen-1 | 2 | 2012 | 30 | 0.760 |
Why?
| Neuroprotective Agents | 1 | 2022 | 109 | 0.750 |
Why?
| Ophthalmoscopes | 1 | 2021 | 2 | 0.750 |
Why?
| Viscosity | 2 | 2020 | 89 | 0.740 |
Why?
| Glaucoma | 4 | 2020 | 219 | 0.740 |
Why?
| Administration, Ophthalmic | 8 | 2021 | 14 | 0.730 |
Why?
| Peptides | 5 | 2022 | 915 | 0.700 |
Why?
| Water | 3 | 2019 | 442 | 0.690 |
Why?
| Molecular Chaperones | 3 | 2022 | 182 | 0.690 |
Why?
| Infusion Pumps, Implantable | 1 | 2020 | 22 | 0.680 |
Why?
| Lens, Crystalline | 4 | 2011 | 122 | 0.680 |
Why?
| Intravitreal Injections | 10 | 2020 | 55 | 0.680 |
Why?
| Peptide Fragments | 4 | 2013 | 688 | 0.680 |
Why?
| Bleomycin | 3 | 2018 | 241 | 0.670 |
Why?
| Injections, Intraocular | 3 | 2017 | 10 | 0.660 |
Why?
| Antihypertensive Agents | 2 | 2014 | 482 | 0.650 |
Why?
| beta-Cyclodextrins | 3 | 2004 | 27 | 0.640 |
Why?
| Fluorescent Dyes | 5 | 2018 | 313 | 0.640 |
Why?
| Genetic Therapy | 5 | 2014 | 292 | 0.630 |
Why?
| Lung Injury | 2 | 2018 | 199 | 0.630 |
Why?
| Macular Degeneration | 5 | 2017 | 157 | 0.630 |
Why?
| Albumins | 2 | 2019 | 101 | 0.630 |
Why?
| Ephrin-A2 | 1 | 2018 | 4 | 0.620 |
Why?
| Microscopy, Confocal | 8 | 2020 | 310 | 0.620 |
Why?
| Mitochondria | 3 | 2022 | 855 | 0.610 |
Why?
| Retinal Diseases | 5 | 2014 | 86 | 0.610 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 758 | 0.610 |
Why?
| Chromatography, High Pressure Liquid | 12 | 2013 | 488 | 0.600 |
Why?
| Cell Line | 17 | 2018 | 2741 | 0.600 |
Why?
| Lung | 5 | 2018 | 3748 | 0.600 |
Why?
| Biological Transport | 9 | 2012 | 396 | 0.600 |
Why?
| Lipid Bilayers | 1 | 2019 | 98 | 0.590 |
Why?
| Biological Availability | 9 | 2020 | 131 | 0.590 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 100 | 0.580 |
Why?
| Fluorescein-5-isothiocyanate | 4 | 2016 | 37 | 0.580 |
Why?
| Thiophenes | 2 | 2025 | 118 | 0.570 |
Why?
| Microspheres | 4 | 2012 | 125 | 0.570 |
Why?
| Area Under Curve | 7 | 2020 | 293 | 0.560 |
Why?
| Fluorescein | 4 | 2018 | 25 | 0.560 |
Why?
| Needles | 1 | 2017 | 56 | 0.560 |
Why?
| Permeability | 9 | 2018 | 156 | 0.560 |
Why?
| Technology, Pharmaceutical | 2 | 2010 | 18 | 0.560 |
Why?
| Retinitis Pigmentosa | 2 | 2014 | 20 | 0.530 |
Why?
| Rats, Inbred BN | 8 | 2011 | 54 | 0.530 |
Why?
| Cataract | 2 | 2011 | 208 | 0.520 |
Why?
| Antineoplastic Agents | 6 | 2022 | 2042 | 0.510 |
Why?
| Cephalosporins | 3 | 2002 | 40 | 0.510 |
Why?
| Nanocapsules | 2 | 2013 | 10 | 0.510 |
Why?
| Electric Impedance | 4 | 2014 | 101 | 0.490 |
Why?
| Dogs | 4 | 2025 | 368 | 0.490 |
Why?
| Endothelial Cells | 3 | 2018 | 703 | 0.490 |
Why?
| RNA, Messenger | 16 | 2012 | 2679 | 0.480 |
Why?
| Dinoprostone | 3 | 2009 | 187 | 0.480 |
Why?
| Humans | 66 | 2025 | 128495 | 0.480 |
Why?
| Epithelium, Corneal | 6 | 2018 | 40 | 0.480 |
Why?
| Exfoliation Syndrome | 1 | 2014 | 10 | 0.470 |
Why?
| Leukostasis | 2 | 2011 | 2 | 0.470 |
Why?
| Pyridones | 2 | 2013 | 158 | 0.460 |
Why?
| Disease Models, Animal | 15 | 2018 | 3947 | 0.460 |
Why?
| Chemical Phenomena | 2 | 2011 | 81 | 0.440 |
Why?
| Light | 2 | 2013 | 353 | 0.430 |
Why?
| Transferrin | 3 | 2009 | 42 | 0.430 |
Why?
| Posterior Eye Segment | 1 | 2013 | 2 | 0.420 |
Why?
| Chloroquine | 2 | 2012 | 52 | 0.420 |
Why?
| Eye Proteins | 2 | 2012 | 88 | 0.420 |
Why?
| Serum Albumin, Bovine | 1 | 2013 | 62 | 0.420 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2018 | 1187 | 0.420 |
Why?
| Glaucoma, Open-Angle | 1 | 2014 | 101 | 0.420 |
Why?
| Cell Proliferation | 8 | 2017 | 2345 | 0.410 |
Why?
| Poloxamer | 2 | 2002 | 11 | 0.410 |
Why?
| Nanomedicine | 1 | 2013 | 31 | 0.410 |
Why?
| Salicylic Acid | 1 | 2012 | 8 | 0.410 |
Why?
| Mice | 23 | 2023 | 16620 | 0.410 |
Why?
| Capsid Proteins | 1 | 2013 | 90 | 0.400 |
Why?
| Adenoviridae | 1 | 2013 | 189 | 0.400 |
Why?
| Phenylalanine | 1 | 2012 | 65 | 0.400 |
Why?
| Fluocinolone Acetonide | 2 | 2011 | 19 | 0.400 |
Why?
| Male | 44 | 2020 | 63043 | 0.400 |
Why?
| Pyrimidines | 2 | 2017 | 449 | 0.400 |
Why?
| Cyclooxygenase 2 | 4 | 2012 | 178 | 0.400 |
Why?
| Geographic Atrophy | 1 | 2013 | 69 | 0.390 |
Why?
| Adrenergic beta-Antagonists | 4 | 2011 | 320 | 0.390 |
Why?
| Drug Implants | 3 | 2020 | 83 | 0.390 |
Why?
| Pulmonary Fibrosis | 2 | 2013 | 377 | 0.390 |
Why?
| Chlorides | 4 | 1998 | 137 | 0.390 |
Why?
| Adrenal Cortex Hormones | 3 | 2021 | 518 | 0.390 |
Why?
| Bronchodilator Agents | 2 | 2005 | 243 | 0.390 |
Why?
| Corneal Neovascularization | 4 | 2015 | 15 | 0.380 |
Why?
| Drug Liberation | 3 | 2021 | 29 | 0.380 |
Why?
| Injections | 8 | 2011 | 173 | 0.380 |
Why?
| Probenecid | 2 | 2009 | 8 | 0.380 |
Why?
| Tyrosine | 1 | 2012 | 218 | 0.380 |
Why?
| Antioxidants | 2 | 2014 | 545 | 0.380 |
Why?
| Carbon Dioxide | 4 | 2013 | 258 | 0.370 |
Why?
| STAT1 Transcription Factor | 1 | 2011 | 70 | 0.370 |
Why?
| Thiazines | 1 | 2011 | 9 | 0.370 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 89 | 0.370 |
Why?
| Macular Edema | 1 | 2011 | 42 | 0.360 |
Why?
| Bevacizumab | 4 | 2017 | 129 | 0.360 |
Why?
| Oxidative Stress | 5 | 2021 | 1191 | 0.360 |
Why?
| Absorbable Implants | 2 | 2020 | 35 | 0.360 |
Why?
| Oligonucleotides, Antisense | 3 | 2009 | 106 | 0.360 |
Why?
| Mitochondrial Diseases | 1 | 2011 | 90 | 0.360 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 941 | 0.350 |
Why?
| Polyglactin 910 | 2 | 2012 | 6 | 0.350 |
Why?
| Poly G | 1 | 2010 | 2 | 0.350 |
Why?
| Suspensions | 3 | 2020 | 36 | 0.340 |
Why?
| Diclofenac | 2 | 2009 | 14 | 0.340 |
Why?
| Trabecular Meshwork | 1 | 2011 | 79 | 0.340 |
Why?
| Vascular Endothelial Growth Factors | 6 | 2011 | 65 | 0.340 |
Why?
| Micelles | 1 | 2010 | 37 | 0.340 |
Why?
| Fluoroquinolones | 1 | 2010 | 45 | 0.340 |
Why?
| Solvents | 5 | 2013 | 108 | 0.340 |
Why?
| Solubility | 5 | 2011 | 234 | 0.340 |
Why?
| Vascular Diseases | 1 | 2012 | 232 | 0.330 |
Why?
| Retinal Neovascularization | 4 | 2015 | 22 | 0.330 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2009 | 10 | 0.330 |
Why?
| Drug Stability | 6 | 2011 | 149 | 0.330 |
Why?
| Receptors, Glucocorticoid | 2 | 2009 | 148 | 0.320 |
Why?
| Chorioallantoic Membrane | 1 | 2009 | 3 | 0.320 |
Why?
| Gene Expression | 5 | 2018 | 1455 | 0.320 |
Why?
| Porosity | 4 | 2013 | 94 | 0.320 |
Why?
| Cell Survival | 6 | 2013 | 1076 | 0.310 |
Why?
| Taxoids | 1 | 2009 | 98 | 0.310 |
Why?
| Lung Neoplasms | 5 | 2017 | 2329 | 0.310 |
Why?
| Quantitative Structure-Activity Relationship | 1 | 2008 | 14 | 0.310 |
Why?
| Plasmids | 5 | 2017 | 355 | 0.300 |
Why?
| Receptor, EphA2 | 2 | 2018 | 20 | 0.300 |
Why?
| Endothelium, Corneal | 2 | 2021 | 16 | 0.300 |
Why?
| Spectroscopy, Fourier Transform Infrared | 4 | 2010 | 82 | 0.300 |
Why?
| Models, Animal | 2 | 2020 | 367 | 0.300 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1951 | 0.300 |
Why?
| Pharmacokinetics | 4 | 2012 | 25 | 0.300 |
Why?
| Injections, Intravenous | 5 | 2017 | 197 | 0.300 |
Why?
| Green Fluorescent Proteins | 1 | 2009 | 380 | 0.290 |
Why?
| Eye Color | 1 | 2008 | 3 | 0.290 |
Why?
| Bruch Membrane | 2 | 2011 | 6 | 0.290 |
Why?
| Retinal Pigments | 1 | 2007 | 5 | 0.290 |
Why?
| Protein-Tyrosine Kinases | 1 | 2011 | 431 | 0.290 |
Why?
| Drug Administration Routes | 4 | 2009 | 38 | 0.290 |
Why?
| DNA-Binding Proteins | 3 | 2023 | 1423 | 0.290 |
Why?
| Photosensitizing Agents | 1 | 2008 | 31 | 0.290 |
Why?
| Lasers | 3 | 2021 | 132 | 0.280 |
Why?
| Anthraquinones | 1 | 2007 | 10 | 0.280 |
Why?
| Anti-Infective Agents | 1 | 2010 | 245 | 0.280 |
Why?
| Chemistry, Pharmaceutical | 4 | 2012 | 104 | 0.280 |
Why?
| Imidazolidines | 1 | 2007 | 10 | 0.280 |
Why?
| Fluorophotometry | 2 | 2020 | 3 | 0.280 |
Why?
| Indomethacin | 2 | 2004 | 77 | 0.280 |
Why?
| Medical Oncology | 1 | 2009 | 272 | 0.280 |
Why?
| ELAV-Like Protein 1 | 2 | 2017 | 16 | 0.270 |
Why?
| Microscopy, Electron, Scanning | 5 | 2005 | 195 | 0.270 |
Why?
| Macula Lutea | 1 | 2007 | 21 | 0.270 |
Why?
| DNA | 2 | 2013 | 1394 | 0.270 |
Why?
| Rhodamines | 1 | 2006 | 17 | 0.270 |
Why?
| Mannitol | 1 | 2006 | 35 | 0.270 |
Why?
| Serum Albumin | 1 | 2007 | 146 | 0.260 |
Why?
| Reproducibility of Results | 3 | 2022 | 3021 | 0.260 |
Why?
| Blotting, Western | 7 | 2013 | 1170 | 0.260 |
Why?
| Time Factors | 13 | 2015 | 6505 | 0.250 |
Why?
| Protein Kinase Inhibitors | 1 | 2011 | 880 | 0.240 |
Why?
| Hydrogen-Ion Concentration | 5 | 2015 | 541 | 0.240 |
Why?
| Aldehydes | 2 | 2005 | 138 | 0.240 |
Why?
| Mites | 1 | 2025 | 6 | 0.240 |
Why?
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 820 | 0.240 |
Why?
| Oxazoles | 1 | 2025 | 30 | 0.240 |
Why?
| Superoxide Dismutase | 1 | 2007 | 337 | 0.230 |
Why?
| Triamcinolone Acetonide | 3 | 2021 | 27 | 0.230 |
Why?
| Swine | 5 | 2021 | 742 | 0.230 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2013 | 510 | 0.230 |
Why?
| Cats | 1 | 2025 | 209 | 0.230 |
Why?
| Buserelin | 1 | 2004 | 1 | 0.230 |
Why?
| Glutathione | 2 | 2005 | 341 | 0.230 |
Why?
| Oligopeptides | 3 | 2011 | 255 | 0.220 |
Why?
| Cell Line, Tumor | 7 | 2022 | 3178 | 0.220 |
Why?
| Orphan Nuclear Receptors | 3 | 2014 | 15 | 0.220 |
Why?
| DNA Helicases | 2 | 2023 | 149 | 0.220 |
Why?
| Cell Membrane Permeability | 4 | 2018 | 80 | 0.220 |
Why?
| In Vitro Techniques | 6 | 2012 | 1047 | 0.220 |
Why?
| Lysosomes | 2 | 2015 | 135 | 0.210 |
Why?
| Protein Synthesis Inhibitors | 2 | 2014 | 44 | 0.210 |
Why?
| Half-Life | 3 | 2009 | 152 | 0.210 |
Why?
| Mice, Inbred BALB C | 6 | 2014 | 1227 | 0.210 |
Why?
| Circular Dichroism | 2 | 2013 | 148 | 0.210 |
Why?
| Cell Cycle | 3 | 2013 | 581 | 0.210 |
Why?
| Respiratory System | 1 | 2004 | 152 | 0.200 |
Why?
| Arthritis, Rheumatoid | 1 | 2011 | 1088 | 0.200 |
Why?
| Octanols | 1 | 2022 | 1 | 0.200 |
Why?
| Polyesters | 3 | 2013 | 72 | 0.200 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2002 | 47 | 0.200 |
Why?
| Liposomes | 3 | 2011 | 168 | 0.200 |
Why?
| Protein Structure, Secondary | 2 | 2013 | 340 | 0.200 |
Why?
| Linear Models | 3 | 2009 | 816 | 0.200 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2002 | 36 | 0.190 |
Why?
| Protein Aggregates | 1 | 2022 | 67 | 0.190 |
Why?
| alpha-Cyclodextrins | 1 | 2001 | 1 | 0.190 |
Why?
| Cyclodextrins | 1 | 2001 | 7 | 0.190 |
Why?
| Thiazolidinediones | 2 | 2013 | 137 | 0.190 |
Why?
| Transfection | 3 | 2015 | 896 | 0.190 |
Why?
| Chymotrypsin | 1 | 2001 | 19 | 0.190 |
Why?
| Temperature | 5 | 2004 | 632 | 0.190 |
Why?
| Drug Evaluation, Preclinical | 4 | 2017 | 168 | 0.190 |
Why?
| Biocompatible Materials | 2 | 2020 | 396 | 0.190 |
Why?
| Rhodopsin | 2 | 2011 | 9 | 0.190 |
Why?
| Electroretinography | 4 | 2018 | 44 | 0.190 |
Why?
| Cystinosis | 1 | 2021 | 1 | 0.190 |
Why?
| Prostatic Neoplasms | 1 | 2009 | 1016 | 0.190 |
Why?
| Contact Lenses | 1 | 2021 | 9 | 0.190 |
Why?
| Cystine | 1 | 2021 | 17 | 0.180 |
Why?
| Models, Molecular | 2 | 2019 | 1484 | 0.180 |
Why?
| Zinc Compounds | 2 | 1998 | 7 | 0.180 |
Why?
| Edetic Acid | 2 | 1998 | 46 | 0.180 |
Why?
| Carboplatin | 2 | 2013 | 140 | 0.180 |
Why?
| Oncogenes | 2 | 2022 | 111 | 0.180 |
Why?
| Brain | 2 | 2011 | 2624 | 0.180 |
Why?
| Eye Burns | 2 | 2013 | 12 | 0.180 |
Why?
| Proteins | 2 | 2001 | 936 | 0.180 |
Why?
| Fluorescein Angiography | 4 | 2017 | 143 | 0.180 |
Why?
| Hypromellose Derivatives | 1 | 2020 | 1 | 0.180 |
Why?
| Uveitis | 2 | 2014 | 127 | 0.180 |
Why?
| Molecular Weight | 2 | 2013 | 331 | 0.180 |
Why?
| Therapeutic Equivalency | 1 | 2020 | 21 | 0.180 |
Why?
| Collagen | 2 | 2013 | 430 | 0.170 |
Why?
| Cytoskeleton | 1 | 2021 | 180 | 0.170 |
Why?
| Respiratory Mucosa | 1 | 2003 | 304 | 0.170 |
Why?
| Mice, Nude | 3 | 2017 | 678 | 0.170 |
Why?
| Corneal Stroma | 2 | 2018 | 17 | 0.170 |
Why?
| Symporters | 1 | 2020 | 54 | 0.170 |
Why?
| Prodrugs | 1 | 2000 | 48 | 0.170 |
Why?
| Cholic Acids | 2 | 2011 | 17 | 0.170 |
Why?
| Ophthalmology | 1 | 2021 | 82 | 0.170 |
Why?
| Pyramidal Cells | 1 | 2020 | 70 | 0.170 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 66 | 0.170 |
Why?
| Benzo(a)pyrene | 2 | 2013 | 7 | 0.170 |
Why?
| Administration, Oral | 3 | 2012 | 767 | 0.170 |
Why?
| 2-Hydroxypropyl-beta-cyclodextrin | 3 | 2004 | 6 | 0.160 |
Why?
| Body Weight | 3 | 2011 | 933 | 0.160 |
Why?
| Prednisolone | 2 | 2011 | 82 | 0.160 |
Why?
| Thermodynamics | 1 | 2001 | 407 | 0.160 |
Why?
| Gene Expression Regulation | 6 | 2018 | 2516 | 0.160 |
Why?
| Drug Monitoring | 1 | 2020 | 190 | 0.160 |
Why?
| Synovial Fluid | 1 | 1999 | 66 | 0.160 |
Why?
| Adsorption | 1 | 2019 | 139 | 0.150 |
Why?
| Chitosan | 2 | 2016 | 32 | 0.150 |
Why?
| Models, Biological | 3 | 2013 | 1698 | 0.150 |
Why?
| Molecular Targeted Therapy | 2 | 2011 | 385 | 0.150 |
Why?
| Drug Administration Schedule | 2 | 2011 | 764 | 0.150 |
Why?
| Mice, Inbred C57BL | 8 | 2018 | 5281 | 0.150 |
Why?
| Chemistry, Physical | 2 | 2009 | 37 | 0.150 |
Why?
| Surface Properties | 1 | 2019 | 394 | 0.140 |
Why?
| Cells, Cultured | 6 | 2018 | 4017 | 0.140 |
Why?
| Glioma | 1 | 2022 | 354 | 0.140 |
Why?
| Gene Silencing | 3 | 2017 | 183 | 0.140 |
Why?
| Neovascularization, Pathologic | 2 | 2013 | 290 | 0.140 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2018 | 101 | 0.140 |
Why?
| Drug Interactions | 3 | 2013 | 361 | 0.140 |
Why?
| Regional Blood Flow | 2 | 2011 | 458 | 0.140 |
Why?
| Molecular Structure | 2 | 2009 | 466 | 0.140 |
Why?
| Endoplasmic Reticulum | 2 | 2018 | 260 | 0.140 |
Why?
| Drug Combinations | 2 | 2011 | 324 | 0.140 |
Why?
| Glycoproteins | 1 | 1999 | 337 | 0.140 |
Why?
| Action Potentials | 1 | 2020 | 469 | 0.140 |
Why?
| Excipients | 2 | 2001 | 51 | 0.140 |
Why?
| Turbinates | 2 | 2008 | 16 | 0.130 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2013 | 624 | 0.130 |
Why?
| Dextran Sulfate | 1 | 2016 | 77 | 0.130 |
Why?
| RNAi Therapeutics | 1 | 2016 | 4 | 0.130 |
Why?
| Mifepristone | 2 | 2009 | 62 | 0.130 |
Why?
| Folate Receptor 1 | 1 | 2016 | 15 | 0.130 |
Why?
| 2,4-Dinitrophenol | 3 | 2004 | 8 | 0.130 |
Why?
| Surgeons | 1 | 2020 | 259 | 0.130 |
Why?
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 42 | 0.130 |
Why?
| Immunoconjugates | 1 | 2017 | 103 | 0.130 |
Why?
| Transient Receptor Potential Channels | 1 | 2015 | 5 | 0.120 |
Why?
| Indazoles | 2 | 2017 | 65 | 0.120 |
Why?
| Central Nervous System | 1 | 1998 | 254 | 0.120 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2015 | 14 | 0.120 |
Why?
| Presenilin-1 | 1 | 2015 | 31 | 0.120 |
Why?
| Signal Transduction | 2 | 2013 | 4825 | 0.120 |
Why?
| Precision Medicine | 1 | 2019 | 386 | 0.120 |
Why?
| Hippocampus | 1 | 2020 | 832 | 0.120 |
Why?
| Female | 16 | 2020 | 68266 | 0.120 |
Why?
| Wnt3A Protein | 1 | 2015 | 10 | 0.120 |
Why?
| Receptors, LDL | 1 | 2015 | 46 | 0.120 |
Why?
| Cyclic AMP | 1 | 1996 | 231 | 0.120 |
Why?
| Mucous Membrane | 3 | 1996 | 121 | 0.120 |
Why?
| Sodium | 2 | 1996 | 202 | 0.120 |
Why?
| Absorption | 2 | 2004 | 57 | 0.120 |
Why?
| Administration, Intranasal | 2 | 2009 | 83 | 0.120 |
Why?
| Vaccine Potency | 1 | 2014 | 6 | 0.110 |
Why?
| Phagocytosis | 2 | 2013 | 361 | 0.110 |
Why?
| Retinal Vessels | 1 | 2015 | 65 | 0.110 |
Why?
| Aluminum Hydroxide | 1 | 2014 | 12 | 0.110 |
Why?
| Injections, Intraperitoneal | 2 | 2004 | 109 | 0.110 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 324 | 0.110 |
Why?
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.110 |
Why?
| Plasminogen | 2 | 2011 | 31 | 0.110 |
Why?
| Microbial Sensitivity Tests | 2 | 2010 | 352 | 0.110 |
Why?
| Eye Diseases, Hereditary | 1 | 2014 | 11 | 0.110 |
Why?
| Freezing | 1 | 2014 | 86 | 0.110 |
Why?
| Blood Glucose | 3 | 2011 | 2092 | 0.110 |
Why?
| Hepatitis B Vaccines | 1 | 2014 | 47 | 0.110 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 73 | 0.110 |
Why?
| Acetophenones | 1 | 2013 | 13 | 0.110 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 117 | 0.110 |
Why?
| Fibrosis | 2 | 2013 | 513 | 0.110 |
Why?
| Withanolides | 1 | 2013 | 1 | 0.110 |
Why?
| Tight Junctions | 1 | 2014 | 74 | 0.110 |
Why?
| Calorimetry, Differential Scanning | 2 | 2004 | 36 | 0.110 |
Why?
| Micro-Electrical-Mechanical Systems | 1 | 2013 | 5 | 0.110 |
Why?
| Cholesterol | 2 | 2016 | 406 | 0.110 |
Why?
| Chromatography, Gel | 1 | 2013 | 127 | 0.110 |
Why?
| Retinal Rod Photoreceptor Cells | 1 | 2013 | 13 | 0.110 |
Why?
| Wnt Signaling Pathway | 1 | 2015 | 166 | 0.100 |
Why?
| Cell Shape | 1 | 2013 | 55 | 0.100 |
Why?
| alpha-Crystallin A Chain | 1 | 2013 | 13 | 0.100 |
Why?
| Trachea | 2 | 2005 | 221 | 0.100 |
Why?
| L-Lactate Dehydrogenase | 1 | 2013 | 116 | 0.100 |
Why?
| Gemfibrozil | 1 | 2013 | 11 | 0.100 |
Why?
| Capsid | 1 | 2013 | 90 | 0.100 |
Why?
| Scattering, Radiation | 1 | 2013 | 99 | 0.100 |
Why?
| Monophenol Monooxygenase | 1 | 2012 | 7 | 0.100 |
Why?
| Vimentin | 1 | 2013 | 50 | 0.100 |
Why?
| Madin Darby Canine Kidney Cells | 1 | 2012 | 14 | 0.100 |
Why?
| Receptors, Transferrin | 2 | 2017 | 23 | 0.100 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 137 | 0.100 |
Why?
| Treatment Outcome | 6 | 2014 | 10162 | 0.100 |
Why?
| Adjuvants, Immunologic | 1 | 2014 | 221 | 0.100 |
Why?
| Timolol | 2 | 2011 | 14 | 0.100 |
Why?
| Levodopa | 1 | 2012 | 29 | 0.100 |
Why?
| Vision Disorders | 1 | 2014 | 135 | 0.100 |
Why?
| Pressure | 1 | 2013 | 237 | 0.100 |
Why?
| Protein Stability | 1 | 2013 | 160 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2008 | 1817 | 0.100 |
Why?
| Bronchoalveolar Lavage | 1 | 2012 | 89 | 0.100 |
Why?
| Corneal Injuries | 1 | 2013 | 50 | 0.100 |
Why?
| Gels | 2 | 2002 | 82 | 0.100 |
Why?
| Ouabain | 3 | 1998 | 18 | 0.100 |
Why?
| Cell Count | 1 | 2013 | 310 | 0.100 |
Why?
| Pigmentation | 1 | 2012 | 51 | 0.100 |
Why?
| Colorimetry | 1 | 2012 | 12 | 0.100 |
Why?
| Corneal Diseases | 1 | 2012 | 34 | 0.100 |
Why?
| Lymphangiogenesis | 1 | 2012 | 25 | 0.100 |
Why?
| Doxycycline | 1 | 2012 | 57 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 205 | 0.100 |
Why?
| Hypolipidemic Agents | 1 | 2013 | 92 | 0.100 |
Why?
| Macaca fascicularis | 1 | 2012 | 49 | 0.100 |
Why?
| Aqueous Humor | 2 | 2014 | 33 | 0.100 |
Why?
| Endothelium, Vascular | 1 | 2018 | 844 | 0.100 |
Why?
| Cloning, Molecular | 1 | 2013 | 522 | 0.100 |
Why?
| Inflammation | 2 | 2020 | 2666 | 0.100 |
Why?
| Apoptosis | 4 | 2013 | 2437 | 0.100 |
Why?
| Membrane Transport Proteins | 1 | 2013 | 149 | 0.100 |
Why?
| Paclitaxel | 1 | 2013 | 214 | 0.100 |
Why?
| Swine, Miniature | 1 | 2012 | 79 | 0.100 |
Why?
| Microscopy, Phase-Contrast | 1 | 2011 | 15 | 0.090 |
Why?
| Computer Simulation | 2 | 2018 | 939 | 0.090 |
Why?
| Drug Discovery | 1 | 2012 | 130 | 0.090 |
Why?
| MicroRNAs | 1 | 2018 | 674 | 0.090 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2017 | 812 | 0.090 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2011 | 14 | 0.090 |
Why?
| Propranolol | 1 | 2011 | 50 | 0.090 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2011 | 68 | 0.090 |
Why?
| Carbon | 1 | 2012 | 208 | 0.090 |
Why?
| Amino Acids | 1 | 1995 | 477 | 0.090 |
Why?
| Optic Nerve | 1 | 2011 | 64 | 0.090 |
Why?
| Quinoxalines | 1 | 2011 | 65 | 0.090 |
Why?
| Curcumin | 1 | 2011 | 28 | 0.090 |
Why?
| Diffusion Chambers, Culture | 2 | 2010 | 8 | 0.090 |
Why?
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 74 | 0.090 |
Why?
| Biological Transport, Active | 4 | 2010 | 72 | 0.090 |
Why?
| Rats, Wistar | 1 | 2012 | 398 | 0.090 |
Why?
| HEK293 Cells | 1 | 2013 | 683 | 0.090 |
Why?
| Anti-Bacterial Agents | 2 | 2012 | 1705 | 0.090 |
Why?
| Wound Healing | 1 | 2013 | 301 | 0.090 |
Why?
| Materials Testing | 1 | 2012 | 345 | 0.090 |
Why?
| Ion Transport | 3 | 1996 | 57 | 0.090 |
Why?
| Silymarin | 1 | 2012 | 199 | 0.090 |
Why?
| Gold | 2 | 2022 | 118 | 0.090 |
Why?
| Lipogenesis | 1 | 2011 | 59 | 0.090 |
Why?
| Chemical Warfare Agents | 1 | 2012 | 121 | 0.090 |
Why?
| Pregnadienediols | 1 | 2010 | 4 | 0.090 |
Why?
| Cross-Sectional Studies | 1 | 2021 | 5045 | 0.090 |
Why?
| Chromatography, Supercritical Fluid | 1 | 2009 | 3 | 0.080 |
Why?
| Calorimetry | 1 | 2010 | 64 | 0.080 |
Why?
| Leukocytes | 1 | 2011 | 303 | 0.080 |
Why?
| Stress, Physiological | 1 | 2013 | 413 | 0.080 |
Why?
| Emulsions | 1 | 2009 | 45 | 0.080 |
Why?
| Interleukin-10 | 1 | 2011 | 299 | 0.080 |
Why?
| Polymorphism, Genetic | 1 | 2013 | 639 | 0.080 |
Why?
| Dosage Forms | 1 | 2009 | 10 | 0.080 |
Why?
| Blood Proteins | 1 | 2011 | 240 | 0.080 |
Why?
| Flow Cytometry | 2 | 2012 | 1142 | 0.080 |
Why?
| Graft Survival | 1 | 2012 | 503 | 0.080 |
Why?
| Neoplasm Transplantation | 1 | 2009 | 257 | 0.080 |
Why?
| Calcium | 1 | 2015 | 1183 | 0.080 |
Why?
| Retinal Neoplasms | 1 | 2009 | 26 | 0.080 |
Why?
| Retinoblastoma | 1 | 2009 | 31 | 0.080 |
Why?
| Neoplasms | 1 | 2023 | 2463 | 0.080 |
Why?
| Aging | 1 | 2019 | 1755 | 0.080 |
Why?
| Chick Embryo | 1 | 2009 | 130 | 0.080 |
Why?
| Genetic Vectors | 2 | 2007 | 311 | 0.080 |
Why?
| Anticholesteremic Agents | 1 | 2011 | 146 | 0.080 |
Why?
| Vinblastine | 1 | 2009 | 68 | 0.080 |
Why?
| Least-Squares Analysis | 1 | 2008 | 72 | 0.080 |
Why?
| Cell Membrane | 1 | 2012 | 725 | 0.080 |
Why?
| Drug Synergism | 1 | 2009 | 357 | 0.080 |
Why?
| Calibration | 1 | 2008 | 135 | 0.080 |
Why?
| Tumor Burden | 1 | 2009 | 284 | 0.070 |
Why?
| Validation Studies as Topic | 1 | 2008 | 21 | 0.070 |
Why?
| Thionucleotides | 1 | 2007 | 34 | 0.070 |
Why?
| Photochemotherapy | 1 | 2008 | 32 | 0.070 |
Why?
| Tosylphenylalanyl Chloromethyl Ketone | 2 | 1998 | 3 | 0.070 |
Why?
| Hydrocortisone | 1 | 2010 | 304 | 0.070 |
Why?
| Mice, Transgenic | 4 | 2018 | 2069 | 0.070 |
Why?
| Ethylmaleimide | 2 | 1998 | 18 | 0.070 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 172 | 0.070 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2007 | 92 | 0.070 |
Why?
| Lipid Metabolism | 1 | 2011 | 492 | 0.070 |
Why?
| Caveolae | 1 | 2007 | 16 | 0.070 |
Why?
| Cell Movement | 3 | 2017 | 936 | 0.070 |
Why?
| Models, Anatomic | 1 | 2008 | 89 | 0.070 |
Why?
| Clathrin | 1 | 2007 | 26 | 0.070 |
Why?
| Pharmaceutical Vehicles | 1 | 2007 | 11 | 0.070 |
Why?
| Species Specificity | 1 | 2008 | 569 | 0.070 |
Why?
| Mydriasis | 1 | 2007 | 7 | 0.070 |
Why?
| Galactose | 1 | 2007 | 28 | 0.070 |
Why?
| Vacuoles | 1 | 2007 | 36 | 0.070 |
Why?
| Glycopeptides | 2 | 1998 | 44 | 0.070 |
Why?
| Cells | 1 | 2007 | 24 | 0.070 |
Why?
| Doxorubicin | 1 | 2009 | 324 | 0.070 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 222 | 0.070 |
Why?
| Pulmonary Alveoli | 1 | 2009 | 365 | 0.070 |
Why?
| Burns, Chemical | 1 | 2007 | 29 | 0.070 |
Why?
| Aptamers, Nucleotide | 1 | 2007 | 77 | 0.070 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 216 | 0.070 |
Why?
| Macaca mulatta | 1 | 2007 | 147 | 0.070 |
Why?
| Macrophages | 2 | 2011 | 1464 | 0.070 |
Why?
| Diffusion | 2 | 2009 | 118 | 0.070 |
Why?
| Ketorolac Tromethamine | 1 | 2006 | 3 | 0.070 |
Why?
| Software | 1 | 2011 | 608 | 0.070 |
Why?
| Cell Hypoxia | 1 | 2007 | 228 | 0.060 |
Why?
| Mass Spectrometry | 1 | 2009 | 663 | 0.060 |
Why?
| Electrophysiology | 3 | 1996 | 205 | 0.060 |
Why?
| Alzheimer Disease | 1 | 2011 | 517 | 0.060 |
Why?
| Hydrogels | 1 | 2012 | 638 | 0.060 |
Why?
| Thiobarbituric Acid Reactive Substances | 1 | 2005 | 30 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2005 | 31 | 0.060 |
Why?
| Kidney | 1 | 2012 | 1310 | 0.060 |
Why?
| Lymph Nodes | 1 | 2008 | 466 | 0.060 |
Why?
| Injections, Intramuscular | 1 | 2005 | 115 | 0.060 |
Why?
| Dextrans | 2 | 2016 | 82 | 0.060 |
Why?
| Carcinogens | 1 | 2005 | 110 | 0.060 |
Why?
| Cyclooxygenase 1 | 1 | 2004 | 26 | 0.060 |
Why?
| Oligoribonucleotides, Antisense | 1 | 2004 | 3 | 0.060 |
Why?
| Pharmaceutical Solutions | 1 | 2004 | 14 | 0.060 |
Why?
| X-Ray Diffraction | 1 | 2004 | 94 | 0.060 |
Why?
| Powders | 1 | 2004 | 43 | 0.060 |
Why?
| Antibodies, Monoclonal | 1 | 2011 | 1357 | 0.060 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1562 | 0.060 |
Why?
| Atherosclerosis | 1 | 2008 | 403 | 0.060 |
Why?
| Immunohistochemistry | 3 | 2013 | 1668 | 0.060 |
Why?
| Cell Nucleus | 1 | 2007 | 580 | 0.060 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 1217 | 0.050 |
Why?
| Cell Culture Techniques | 1 | 2006 | 345 | 0.050 |
Why?
| Fluorescent Antibody Technique | 1 | 2004 | 370 | 0.050 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1938 | 0.050 |
Why?
| Diabetes Mellitus | 1 | 2011 | 996 | 0.050 |
Why?
| Cytochrome P-450 CYP2C8 | 2 | 2013 | 12 | 0.050 |
Why?
| Hormone Antagonists | 1 | 2003 | 31 | 0.050 |
Why?
| Cytosol | 1 | 2003 | 215 | 0.050 |
Why?
| Administration, Inhalation | 1 | 2004 | 661 | 0.050 |
Why?
| Theranostic Nanomedicine | 1 | 2022 | 12 | 0.050 |
Why?
| Flow Injection Analysis | 1 | 2002 | 5 | 0.050 |
Why?
| Indocyanine Green | 1 | 2022 | 19 | 0.050 |
Why?
| Dialysis | 1 | 2002 | 18 | 0.050 |
Why?
| Phototherapy | 1 | 2022 | 29 | 0.050 |
Why?
| Verapamil | 1 | 2002 | 38 | 0.050 |
Why?
| Fuchs' Endothelial Dystrophy | 1 | 2021 | 1 | 0.050 |
Why?
| Lipid Peroxidation | 1 | 2002 | 149 | 0.050 |
Why?
| Chemical Precipitation | 1 | 2002 | 37 | 0.050 |
Why?
| Amino Acids, Aromatic | 1 | 2001 | 8 | 0.050 |
Why?
| Isoenzymes | 1 | 2003 | 302 | 0.050 |
Why?
| Capsules | 1 | 2002 | 38 | 0.050 |
Why?
| Chronic Disease | 1 | 2008 | 1692 | 0.050 |
Why?
| Antiviral Agents | 1 | 2007 | 711 | 0.050 |
Why?
| Vincristine | 1 | 2002 | 109 | 0.050 |
Why?
| Solutions | 1 | 2002 | 148 | 0.050 |
Why?
| Tetrazolium Salts | 1 | 2001 | 17 | 0.050 |
Why?
| Antimetabolites | 1 | 2001 | 22 | 0.050 |
Why?
| Indicators and Reagents | 1 | 2001 | 107 | 0.050 |
Why?
| Drug Design | 1 | 2022 | 155 | 0.050 |
Why?
| Ascorbic Acid | 1 | 2021 | 119 | 0.040 |
Why?
| Middle Aged | 5 | 2018 | 30921 | 0.040 |
Why?
| Spectrometry, Fluorescence | 1 | 2001 | 171 | 0.040 |
Why?
| Thiazoles | 1 | 2001 | 115 | 0.040 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 268 | 0.040 |
Why?
| Metal Nanoparticles | 1 | 2021 | 82 | 0.040 |
Why?
| Carcinogenesis | 1 | 2022 | 213 | 0.040 |
Why?
| Hydrolysis | 1 | 2000 | 184 | 0.040 |
Why?
| Liver X Receptors | 2 | 2011 | 30 | 0.040 |
Why?
| Cold Temperature | 1 | 2001 | 154 | 0.040 |
Why?
| Bronchi | 1 | 2001 | 241 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2001 | 930 | 0.040 |
Why?
| Stereoisomerism | 1 | 1999 | 96 | 0.040 |
Why?
| Mannheimia haemolytica | 1 | 1999 | 1 | 0.040 |
Why?
| Microtubules | 1 | 2021 | 259 | 0.040 |
Why?
| Receptor, TIE-2 | 1 | 2018 | 12 | 0.040 |
Why?
| Protein Conformation | 1 | 2001 | 854 | 0.040 |
Why?
| Instillation, Drug | 1 | 2018 | 10 | 0.040 |
Why?
| Fluorometry | 1 | 2018 | 17 | 0.040 |
Why?
| Streptozocin | 1 | 2018 | 16 | 0.040 |
Why?
| Tears | 1 | 2018 | 28 | 0.040 |
Why?
| Membrane Proteins | 1 | 2004 | 1109 | 0.040 |
Why?
| Dithiothreitol | 1 | 1998 | 16 | 0.040 |
Why?
| Random Allocation | 1 | 1999 | 344 | 0.040 |
Why?
| Electroencephalography | 1 | 2020 | 396 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2018 | 140 | 0.040 |
Why?
| Antibiotics, Antineoplastic | 1 | 2018 | 120 | 0.040 |
Why?
| Protein Binding | 1 | 2004 | 2110 | 0.040 |
Why?
| Olfactory Pathways | 1 | 1998 | 60 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 1998 | 89 | 0.030 |
Why?
| Fatty Liver | 2 | 2011 | 231 | 0.030 |
Why?
| G1 Phase | 1 | 2017 | 70 | 0.030 |
Why?
| Static Electricity | 1 | 2017 | 116 | 0.030 |
Why?
| Seizures | 1 | 2020 | 400 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 95 | 0.030 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 168 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1997 | 104 | 0.030 |
Why?
| Staining and Labeling | 1 | 2016 | 137 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 311 | 0.030 |
Why?
| Terbutaline | 1 | 1996 | 6 | 0.030 |
Why?
| Monosaccharide Transport Proteins | 1 | 1996 | 49 | 0.030 |
Why?
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 20 | 0.030 |
Why?
| Visual Acuity | 1 | 2018 | 322 | 0.030 |
Why?
| Colforsin | 1 | 1996 | 49 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2016 | 157 | 0.030 |
Why?
| Complement C3 | 1 | 2017 | 198 | 0.030 |
Why?
| Theophylline | 1 | 1996 | 64 | 0.030 |
Why?
| Endocytosis | 1 | 2016 | 161 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 478 | 0.030 |
Why?
| Phosphodiesterase Inhibitors | 1 | 1996 | 85 | 0.030 |
Why?
| Analysis of Variance | 1 | 2018 | 1273 | 0.030 |
Why?
| Calcium Channel Blockers | 1 | 1996 | 124 | 0.030 |
Why?
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2015 | 4 | 0.030 |
Why?
| Epinephrine | 1 | 1996 | 140 | 0.030 |
Why?
| Adrenergic beta-Agonists | 1 | 1996 | 130 | 0.030 |
Why?
| Folic Acid | 1 | 2016 | 184 | 0.030 |
Why?
| Proteolysis | 1 | 2015 | 162 | 0.030 |
Why?
| Hemoglobins | 1 | 2017 | 337 | 0.030 |
Why?
| Hepatitis B Surface Antigens | 1 | 2014 | 18 | 0.030 |
Why?
| Zonula Occludens-1 Protein | 1 | 2014 | 15 | 0.030 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2014 | 15 | 0.030 |
Why?
| Cycloheximide | 1 | 2014 | 56 | 0.030 |
Why?
| ortho-Aminobenzoates | 1 | 1993 | 8 | 0.030 |
Why?
| Barium Compounds | 1 | 1993 | 7 | 0.030 |
Why?
| Chloride Channels | 1 | 1993 | 38 | 0.030 |
Why?
| Tenon Capsule | 1 | 2013 | 3 | 0.030 |
Why?
| Fundus Oculi | 1 | 2013 | 61 | 0.030 |
Why?
| Diuretics | 1 | 1993 | 75 | 0.030 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2013 | 20 | 0.030 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2013 | 47 | 0.030 |
Why?
| Arginine | 1 | 1995 | 260 | 0.030 |
Why?
| Ion Channels | 1 | 1993 | 127 | 0.030 |
Why?
| Haplorhini | 1 | 2013 | 50 | 0.030 |
Why?
| Lipofuscin | 1 | 2012 | 2 | 0.030 |
Why?
| Pepstatins | 1 | 2012 | 4 | 0.030 |
Why?
| RNA Interference | 1 | 2015 | 441 | 0.030 |
Why?
| beta Catenin | 1 | 2015 | 218 | 0.030 |
Why?
| Cathepsin D | 1 | 2012 | 18 | 0.030 |
Why?
| Opsins | 1 | 2012 | 11 | 0.030 |
Why?
| Autophagy | 1 | 2015 | 265 | 0.030 |
Why?
| Antibody Formation | 1 | 2014 | 290 | 0.030 |
Why?
| Boron Compounds | 1 | 2012 | 22 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 106 | 0.030 |
Why?
| Glaucoma Drainage Implants | 1 | 2013 | 46 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2013 | 181 | 0.020 |
Why?
| Immunoblotting | 1 | 2012 | 301 | 0.020 |
Why?
| Irritants | 1 | 2012 | 48 | 0.020 |
Why?
| Caspase 3 | 1 | 2013 | 230 | 0.020 |
Why?
| Mechlorethamine | 1 | 2012 | 63 | 0.020 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 153 | 0.020 |
Why?
| Catalytic Domain | 1 | 2012 | 217 | 0.020 |
Why?
| Brimonidine Tartrate | 1 | 2011 | 9 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 1996 | 2044 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2014 | 837 | 0.020 |
Why?
| Rats, Transgenic | 1 | 2011 | 15 | 0.020 |
Why?
| Homeostasis | 1 | 2015 | 606 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 310 | 0.020 |
Why?
| Desmosterol | 1 | 2011 | 1 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 1996 | 2822 | 0.020 |
Why?
| Androstenes | 1 | 2011 | 17 | 0.020 |
Why?
| COS Cells | 1 | 2011 | 186 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2011 | 117 | 0.020 |
Why?
| Hep G2 Cells | 1 | 2011 | 61 | 0.020 |
Why?
| Laser Coagulation | 1 | 2011 | 57 | 0.020 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 133 | 0.020 |
Why?
| Adult | 4 | 2018 | 35299 | 0.020 |
Why?
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 23 | 0.020 |
Why?
| Mustard Gas | 1 | 2012 | 110 | 0.020 |
Why?
| Cross-Over Studies | 1 | 2013 | 509 | 0.020 |
Why?
| Intestinal Absorption | 1 | 1991 | 99 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2012 | 399 | 0.020 |
Why?
| Phosphorylation | 1 | 2015 | 1686 | 0.020 |
Why?
| Mutagenesis, Site-Directed | 1 | 2011 | 359 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1349 | 0.020 |
Why?
| Antibodies, Viral | 1 | 2014 | 601 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2014 | 844 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2013 | 1291 | 0.020 |
Why?
| Membrane Potentials | 1 | 2010 | 264 | 0.020 |
Why?
| Young Adult | 2 | 2018 | 12349 | 0.020 |
Why?
| RNA, Ribosomal, 18S | 1 | 2009 | 23 | 0.020 |
Why?
| Ketorolac | 1 | 2009 | 19 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2012 | 1016 | 0.020 |
Why?
| ATP Binding Cassette Transporter 1 | 1 | 2008 | 10 | 0.020 |
Why?
| Foam Cells | 1 | 2008 | 15 | 0.020 |
Why?
| Gene Amplification | 1 | 2009 | 104 | 0.020 |
Why?
| Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 57 | 0.020 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 39 | 0.020 |
Why?
| Apolipoproteins E | 1 | 2008 | 77 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2011 | 1027 | 0.020 |
Why?
| DNA Primers | 1 | 2009 | 510 | 0.020 |
Why?
| Mice, Knockout | 1 | 2015 | 2765 | 0.020 |
Why?
| Fibroblasts | 1 | 2013 | 937 | 0.020 |
Why?
| Feces | 1 | 2011 | 442 | 0.020 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2008 | 130 | 0.020 |
Why?
| Intestines | 1 | 2011 | 344 | 0.020 |
Why?
| Sodium Hydroxide | 1 | 2007 | 8 | 0.020 |
Why?
| Receptors, Peptide | 1 | 2007 | 17 | 0.020 |
Why?
| Cell Fractionation | 1 | 2007 | 56 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2011 | 570 | 0.020 |
Why?
| Models, Theoretical | 1 | 2010 | 542 | 0.020 |
Why?
| Cytomegalovirus | 1 | 2007 | 152 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2011 | 600 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2009 | 859 | 0.020 |
Why?
| Biomedical Research | 1 | 2010 | 633 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2011 | 2719 | 0.010 |
Why?
| Phloretin | 1 | 1996 | 1 | 0.010 |
Why?
| Phlorhizin | 1 | 1996 | 2 | 0.010 |
Why?
| Levobunolol | 1 | 1993 | 1 | 0.010 |
Why?
| Betaxolol | 1 | 1993 | 2 | 0.010 |
Why?
| Atenolol | 1 | 1993 | 6 | 0.010 |
Why?
| Nasolacrimal Duct | 1 | 1993 | 7 | 0.010 |
Why?
| Kinetics | 1 | 1996 | 1623 | 0.010 |
Why?
| Glucose | 1 | 1996 | 983 | 0.010 |
Why?
| Aged | 1 | 2009 | 21974 | 0.010 |
Why?
|
|
Kompella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|